8-KItem 5.07 · Shareholder VoteItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
Bio-Techne shareholders approve Merck KGaA acquisition
Filed with the SEC on · Summarized by InvestorsBot
Bio-Techne shareholders approved the merger agreement for Merck KGaA, Darmstadt, Germany, to acquire the company at a special meeting on September 23, 2026. The Hart-Scott-Rodino waiting period expired on September 18, and Bio-Techne expects the transaction to close by late 2026 or early 2027, subject to remaining regulatory approvals and other customary closing conditions.